<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880554</url>
  </required_header>
  <id_info>
    <org_study_id>IB2010-29</org_study_id>
    <nct_id>NCT01880554</nct_id>
  </id_info>
  <brief_title>Ultrasound Liver Intraoperative Imaging With SonoVue®</brief_title>
  <acronym>ULIIS</acronym>
  <official_title>Clinical Utility of Contrast-enhanced Intraoperative Ultrasound in Surgery of Colorectal Liver Metastases. Phase II Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Use of contrast ultrasound showed interesting results, which can increase&#xD;
      ultrasonography sensitivity performed during surgery in the evaluation of operable liver&#xD;
      metastases.&#xD;
&#xD;
      This study is a two-stage phase II multicenter study (Simon's two-stage).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Use of contrast ultrasound showed interesting results, which can increase&#xD;
      ultrasonography sensitivity performed during surgery in the evaluation of operable liver&#xD;
      metastases.&#xD;
&#xD;
      This study is a two-stage phase II multicenter study (Simon's two-stage).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Utility of Intraoperative Contrast Ultrasound in the Surgery of Colorectal Cancer Liver Metastases.</measure>
    <time_frame>At time of surgery</time_frame>
    <description>The clinical utility will be evaluated in terms of justified modification of the surgical procedure following contrast-enhanced intra-operative ultrasound (CE-IOUS), compared to the surgical procedure following conventional intra-operative ultrasound. For each patient, we will consider CE-IOUS to be clinically useful:&#xD;
if the surgical procedure envisaged at the end of the CE-IOUS is different from the surgical procedure envisaged at the end of the conventional ultrasound&#xD;
and if the surgical procedure envisaged at the end of the CE-IOUS is justified We reported the percentage of patients for whom there was a modified and justified surgical gesture following CE-IOUS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Utility of CE-IOUS in Subgroup of Patients Who Received Preoperative Chemotherapy</measure>
    <time_frame>at time of surgery</time_frame>
    <description>The primary endpoint will be assessed in the subgroup of patients who received preoperative chemotherapy. As for the primary outcome, the clinical utility is evaluated in terms of justified modification of the surgical gesture envisaged following CE-IOUS, compared to the surgical gesture envisaged following a conventional intraoperative ultrasound.&#xD;
We reported the percentage of patients for whom there was a modified and justified surgical gesture following CE-IOUS in the subgroup of patients who received preoperative chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Evaluation of Intraoperative Ultrasound Contrast: Detection Rate Per Lesion</measure>
    <time_frame>up to 3 months after surgery</time_frame>
    <description>Detection of malignant lesions by CE-IOUS in chemotherapy-free patients within 3 post-operative months. The detection rate is defined as the proportion of malignant lesions for which there is concordance between the diagnosis established by CE-IOUS and the reference examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Technical Arrangements for the CE-IOUS</measure>
    <time_frame>At time of contrast-enhanced IOUS</time_frame>
    <description>Description of technical arrangements for the CE-IOUS duration. The length of time during which contrast injection was useable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Evaluation of Intraoperative Ultrasound Contrast Per Lesion: Characterisation Rate</measure>
    <time_frame>up to 3 months after surgery</time_frame>
    <description>Characterisation rate for focal liver lesions: the proportion of lesions whose nature on CE-IOUS is identical to the nature of the lesions defined by the reference examinations among all the lesions seen on CE-IOUS (malignant and benign)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Liver Metastases From Colorectal Primary Cancer</condition>
  <arm_group>
    <arm_group_label>Contrast-enhanced intraoperative ultrasound</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Contrast-enhanced intraoperative ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contrast-enhanced intraoperative ultrasound</intervention_name>
    <description>Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:&#xD;
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages</description>
    <arm_group_label>Contrast-enhanced intraoperative ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with histological proven colorectal cancer.&#xD;
&#xD;
          2. Operable liver metastases according to preoperative imagery. Operability is the&#xD;
             possibility of treatment by resection and/or local destruction (radiofrequency,&#xD;
             cryotherapy…).&#xD;
&#xD;
          3. Patient treated or not with preoperative chemotherapy.&#xD;
&#xD;
          4. With or without extra-hepatic metastases&#xD;
&#xD;
          5. Age ≥ 18 years.&#xD;
&#xD;
          6. Radiological assessment by CT and MRI liver and positron emission tomography scan&#xD;
             (PETscan) within six weeks before surgery.&#xD;
&#xD;
          7. Patient affiliated to the Social Security system.&#xD;
&#xD;
          8. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to sulfur hexafluoride or another component of SonoVue®.&#xD;
&#xD;
          2. Patients with recent acute coronary syndrome or suffering from unstable ischemic heart&#xD;
             disease, especially: evolving myocardial infarction, unstable angina during the last 7&#xD;
             days, recent coronary intervention or another factor suggesting clinical instability,&#xD;
             acute heart failure, class III or IV heart failure, severe arrhythmias.&#xD;
&#xD;
          3. Patients with right-to-left shunt, severe pulmonary arterial hypertension,&#xD;
             uncontrolled systemic hypertension, as patients suffering from respiratory distress&#xD;
             syndrome.&#xD;
&#xD;
          4. Pregnant and lactating women.&#xD;
&#xD;
          5. Patients with contraindication for a CT scan, a MRI or a positron emission tomography&#xD;
             (PET) with contrast.&#xD;
&#xD;
          6. Patients with indication of two step liver surgery.&#xD;
&#xD;
          7. Patients already included in the study.&#xD;
&#xD;
          8. Patient who couldn't be treated or followed up according to study criteria for&#xD;
             psychological, social, family or geographical reasons. Patient deprived of liberty or&#xD;
             under guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EVRARD Serge, PU-PH</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.e-cancer.fr/Professionnels-de-sante/Le-registre-des-essais-cliniques/Le-registre-des-essais-cliniques</url>
    <description>French national cancer institute (INCa) Clinical Trials Registry</description>
  </link>
  <link>
    <url>https://www.bergonie.fr/essais_cliniques/</url>
    <description>Website of the sponsor</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <results_first_submitted>January 5, 2021</results_first_submitted>
  <results_first_submitted_qc>April 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver metastases</keyword>
  <keyword>Colorectal primary cancer</keyword>
  <keyword>Contrast-enhanced ultrasound</keyword>
  <keyword>Sonovue®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Contrast-enhanced Intraoperative Ultrasound</title>
          <description>Contrast-enhanced intraoperative ultrasound&#xD;
Contrast-enhanced intraoperative ultrasound: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:&#xD;
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68">Patients enrolled in the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Population Eligible</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Population Eligible and Assessable</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52">Patients eligible and assessable according to two-stage Simon's design (primary outcome)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Simon's design requirements</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Contrast-enhanced Intraoperative Ultrasound</title>
          <description>Contrast-enhanced intraoperative ultrasound&#xD;
Contrast-enhanced intraoperative ultrasound: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:&#xD;
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer localization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Right Colon</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Colon</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transverse Colon</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver metastases</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Synchronous</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metachronous</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Utility of Intraoperative Contrast Ultrasound in the Surgery of Colorectal Cancer Liver Metastases.</title>
        <description>The clinical utility will be evaluated in terms of justified modification of the surgical procedure following contrast-enhanced intra-operative ultrasound (CE-IOUS), compared to the surgical procedure following conventional intra-operative ultrasound. For each patient, we will consider CE-IOUS to be clinically useful:&#xD;
if the surgical procedure envisaged at the end of the CE-IOUS is different from the surgical procedure envisaged at the end of the conventional ultrasound&#xD;
and if the surgical procedure envisaged at the end of the CE-IOUS is justified We reported the percentage of patients for whom there was a modified and justified surgical gesture following CE-IOUS.</description>
        <time_frame>At time of surgery</time_frame>
        <population>We used a 2-stage Simon's design with the following assumptions:&#xD;
maximum tolerated futility rate: 5%,&#xD;
expected minimum utility rate: 15%,&#xD;
Type I error of 10%,&#xD;
power of 85%. Thus, 52 eligible and evaluable patients were required (25 in the first stage). First stage: stop, if CE-IOUS is not deemed clinically useful for at least one patient (4.0%).&#xD;
Second stage: CE-IOUS clinically useful if the planned surgical procedure is modified and justified for 5 or more patients (9.6%).</population>
        <group_list>
          <group group_id="O1">
            <title>Contrast-enhanced Intraoperative Ultrasound</title>
            <description>Contrast-enhanced intraoperative ultrasound&#xD;
Contrast-enhanced intraoperative ultrasound: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:&#xD;
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages. Step #2 intraoperative ultrasound and step #3 Contrast-enhanced intraoperative ultrasound</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Utility of Intraoperative Contrast Ultrasound in the Surgery of Colorectal Cancer Liver Metastases.</title>
          <description>The clinical utility will be evaluated in terms of justified modification of the surgical procedure following contrast-enhanced intra-operative ultrasound (CE-IOUS), compared to the surgical procedure following conventional intra-operative ultrasound. For each patient, we will consider CE-IOUS to be clinically useful:&#xD;
if the surgical procedure envisaged at the end of the CE-IOUS is different from the surgical procedure envisaged at the end of the conventional ultrasound&#xD;
and if the surgical procedure envisaged at the end of the CE-IOUS is justified We reported the percentage of patients for whom there was a modified and justified surgical gesture following CE-IOUS.</description>
          <population>We used a 2-stage Simon's design with the following assumptions:&#xD;
maximum tolerated futility rate: 5%,&#xD;
expected minimum utility rate: 15%,&#xD;
Type I error of 10%,&#xD;
power of 85%. Thus, 52 eligible and evaluable patients were required (25 in the first stage). First stage: stop, if CE-IOUS is not deemed clinically useful for at least one patient (4.0%).&#xD;
Second stage: CE-IOUS clinically useful if the planned surgical procedure is modified and justified for 5 or more patients (9.6%).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="3.2" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Utility of CE-IOUS in Subgroup of Patients Who Received Preoperative Chemotherapy</title>
        <description>The primary endpoint will be assessed in the subgroup of patients who received preoperative chemotherapy. As for the primary outcome, the clinical utility is evaluated in terms of justified modification of the surgical gesture envisaged following CE-IOUS, compared to the surgical gesture envisaged following a conventional intraoperative ultrasound.&#xD;
We reported the percentage of patients for whom there was a modified and justified surgical gesture following CE-IOUS in the subgroup of patients who received preoperative chemotherapy.</description>
        <time_frame>at time of surgery</time_frame>
        <population>Subgroup of patients with preoperative chemotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Contrast-enhanced Intraoperative Ultrasound</title>
            <description>Contrast-enhanced intraoperative ultrasound&#xD;
Contrast-enhanced intraoperative ultrasound: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:&#xD;
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Utility of CE-IOUS in Subgroup of Patients Who Received Preoperative Chemotherapy</title>
          <description>The primary endpoint will be assessed in the subgroup of patients who received preoperative chemotherapy. As for the primary outcome, the clinical utility is evaluated in terms of justified modification of the surgical gesture envisaged following CE-IOUS, compared to the surgical gesture envisaged following a conventional intraoperative ultrasound.&#xD;
We reported the percentage of patients for whom there was a modified and justified surgical gesture following CE-IOUS in the subgroup of patients who received preoperative chemotherapy.</description>
          <population>Subgroup of patients with preoperative chemotherapy</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" lower_limit="2.52" upper_limit="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance Evaluation of Intraoperative Ultrasound Contrast: Detection Rate Per Lesion</title>
        <description>Detection of malignant lesions by CE-IOUS in chemotherapy-free patients within 3 post-operative months. The detection rate is defined as the proportion of malignant lesions for which there is concordance between the diagnosis established by CE-IOUS and the reference examination.</description>
        <time_frame>up to 3 months after surgery</time_frame>
        <population>There were 22 (40.7%) out of 54 chemotherapy-free patients within 3 post-operative months</population>
        <group_list>
          <group group_id="O1">
            <title>Contrast-enhanced Intraoperative Ultrasound</title>
            <description>Contrast-enhanced intraoperative ultrasound&#xD;
Contrast-enhanced intraoperative ultrasound: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:&#xD;
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Evaluation of Intraoperative Ultrasound Contrast: Detection Rate Per Lesion</title>
          <description>Detection of malignant lesions by CE-IOUS in chemotherapy-free patients within 3 post-operative months. The detection rate is defined as the proportion of malignant lesions for which there is concordance between the diagnosis established by CE-IOUS and the reference examination.</description>
          <population>There were 22 (40.7%) out of 54 chemotherapy-free patients within 3 post-operative months</population>
          <units>proportion of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Description of Technical Arrangements for the CE-IOUS</title>
        <description>Description of technical arrangements for the CE-IOUS duration. The length of time during which contrast injection was useable.</description>
        <time_frame>At time of contrast-enhanced IOUS</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Contrast-enhanced Intraoperative Ultrasound</title>
            <description>Contrast-enhanced intraoperative ultrasound&#xD;
Contrast-enhanced intraoperative ultrasound: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:&#xD;
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages</description>
          </group>
        </group_list>
        <measure>
          <title>Description of Technical Arrangements for the CE-IOUS</title>
          <description>Description of technical arrangements for the CE-IOUS duration. The length of time during which contrast injection was useable.</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225" lower_limit="105" upper_limit="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance Evaluation of Intraoperative Ultrasound Contrast Per Lesion: Characterisation Rate</title>
        <description>Characterisation rate for focal liver lesions: the proportion of lesions whose nature on CE-IOUS is identical to the nature of the lesions defined by the reference examinations among all the lesions seen on CE-IOUS (malignant and benign)</description>
        <time_frame>up to 3 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Contrast-enhanced Intraoperative Ultrasound</title>
            <description>Contrast-enhanced intraoperative ultrasound&#xD;
Contrast-enhanced intraoperative ultrasound: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:&#xD;
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Evaluation of Intraoperative Ultrasound Contrast Per Lesion: Characterisation Rate</title>
          <description>Characterisation rate for focal liver lesions: the proportion of lesions whose nature on CE-IOUS is identical to the nature of the lesions defined by the reference examinations among all the lesions seen on CE-IOUS (malignant and benign)</description>
          <units>proportion of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Contrast-enhanced Intraoperative Ultrasound</title>
          <description>Contrast-enhanced intraoperative ultrasound&#xD;
Contrast-enhanced intraoperative ultrasound: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:&#xD;
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fistule anastomose colorectale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Acute pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Bile collection secondary to a biliary tract wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Stercoral peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Right cry</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Peri-hepatic Blood Collection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Derek Dinart</name_or_title>
      <organization>Institut Bergonie</organization>
      <email>d.dinart@bordeaux.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

